These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31839172)

  • 1. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    Harbeck N; Gluz O
    Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S12-S16. PubMed ID: 35148934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early-stage breast cancer: An Australian institutional real-world experience.
    Narayanan S; Ngui NK; Kinchington B; Choi JDW; Hughes TMD; Rutovitz J; Hasovits C; Nahar KJ; Edirimanne S; Marx G
    Cancer Med; 2024 Jun; 13(12):e7325. PubMed ID: 38899493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience.
    Choi JDW; Hughes TMD; Marx G; Rutovitz J; Hasovits C; Ngui NK
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):103-107. PubMed ID: 31218842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
    Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
    Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
    Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China.
    Wu S; Bian L; Wang H; Zhang S; Wang T; Yu Z; Li J; Li F; Wang K; Jiang Z
    World J Surg Oncol; 2024 Aug; 22(1):214. PubMed ID: 39164763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
    Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
    Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
    Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
    Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.